Skip to main
EDSA
EDSA logo

EDSA Stock Forecast & Price Target

EDSA Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Edesa Biotech Inc's EB01 demonstrated significant improvements in skin health for allergic contact dermatitis (ACD) patients in a Phase 2b trial, indicating the potential for a safer alternative to traditional corticosteroids and calcineurin inhibitors. The ongoing exploration of its drug candidates, including EB05 and EB07, presents opportunities for expansion into new indications and markets, which could enhance projected sales and revenue growth. With a successful track record in clinical trials and a robust pipeline, Edesa Biotech is well-positioned for potential financial gains in the biotechnology sector focused on treating immune-related diseases.

Bears say

Edesa Biotech is projected to experience continued negative cash flows from operating activities through FY2025 and FY2026, indicating a prolonged financial strain. Additionally, the company has faced challenges in its clinical trials, including a higher-than-expected dropout rate that could hinder the progress of its product pipeline. With operating cash flows reported as negative in FY2024, financial stability appears to be a significant concern for the company's future growth prospects.

EDSA has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Edesa Biotech Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Edesa Biotech Inc (EDSA) Forecast

Analysts have given EDSA a Strong Buy based on their latest research and market trends.

According to 1 analysts, EDSA has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Edesa Biotech Inc (EDSA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.